Clinical Trials Logo

Filter by:
NCT ID: NCT01336023 Completed - Clinical trials for Diabetes Mellitus, Type 2

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

DUALâ„¢ I
Start date: May 23, 2011
Phase: Phase 3
Study type: Interventional

This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes. Subjects are to continue their pre-trial treatment with metformin or metformin + pioglitazone throughout the entire trial.

NCT ID: NCT01335061 Completed - Hemophilia B Clinical Trials

Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B

Start date: September 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study will be to determine if a once-weekly prophylaxis regimen of BeneFIX in subjects with moderately severe to severe Hemophilia B is safe and effective.

NCT ID: NCT01333449 Terminated - Clinical trials for Myelodysplastic Syndrome

Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients

Start date: July 2010
Phase: Phase 2
Study type: Interventional

Allogeneic blood stem cell transplant remains the only potential curative treatment for myelodysplastic syndromes (MDS) to date. Pre-transplant induction chemotherapy with leukemia-type regimens is associated with significant toxicity and even death. The hypomethylating agents decitabine and 5-azacytidine have been shown in studies to cause improved hematologic parameters and partial or complete responses in patients with high risk MDS compared to standard therapy. In contrast to leukemia-type chemotherapy, decitabine is associated with a relatively low risk of toxicity. We therefore propose to treat transplant-eligible MDS patients with Decitabine as induction therapy and a bridge to transplant. Hypothesis: 1. Decitabine is able to reduce disease burden as measured by blood and marrow blast counts prior to allogeneic hematopoietic stem cell transplant to below 5%. 2. Decitabine is well-tolerated by patients with high-risk MDS and will be a safe induction agent and bridge prior to allogeneic transplant in transplant-eligible patients.

NCT ID: NCT01330953 Completed - Healthy Volunteers Clinical Trials

A First Human Study of a Ferroportin Antibody

Start date: March 2011
Phase: Phase 1
Study type: Interventional

The purposes of this study are to evaluate the following in healthy participants: 1) LY2928057 safety, including any side effects possibly associated with LY2928057; 2) how the body processes LY2928057; 3) effect of LY2928057 on blood iron levels; and 4) immune system reactions to LY2928057.

NCT ID: NCT01330615 Recruiting - Plantar Warts Clinical Trials

Efficacy Trial of Eutectic Lidocaine/Prilocaine Cream 5% (EMLA) for Analgesia Prior to Cryotherapy of Verrucae Plantaris

Start date: February 2010
Phase: N/A
Study type: Interventional

Aims: The investigators main purpose is to assess the efficacy of analgesia provide by topical lidocaine/prilocaine cream 5% (EMLA)® to pared plantar warts prior to application of liquid nitrogen cryotherapy in adults.

NCT ID: NCT01330602 Recruiting - Clinical trials for Cardiovascular Disease

Intima-Medial Thickness Guidance of Primary Prevention in Relatives of Patients With Early onSet Atherosclerosis

IMPRESS
Start date: May 2010
Phase: N/A
Study type: Interventional

The primary objective of this study is, to instigate a reduction in atherosclerotic burden within the carotid arteries in the intervention group compared to the control group and to demonstrate parallel improvements in cardiovascular and overall health status relative to usual care

NCT ID: NCT01330472 Completed - Healthy Subjects Clinical Trials

An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites

Start date: May 2011
Phase: Phase 1
Study type: Interventional

Study to evaluate if Xanax sustained release tablets manufactured at two different sites provide similar drug levels in the blood.

NCT ID: NCT01327885 Completed - Soft Tissue Sarcoma Clinical Trials

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Start date: March 10, 2011
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multicenter, Phase 3 study comparing the efficacy and safety of eribulin with dacarbazine in subjects with advanced soft tissue sarcoma who have disease progression within 6 months prior to study enrolment following standard therapies which must have included an anthracycline, unless contraindicated and then at least one additional regimen after failure of the anthracycline.

NCT ID: NCT01324479 Completed - Solid Tumors Clinical Trials

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

Start date: February 29, 2012
Phase: Phase 1
Study type: Interventional

This study will assess the safety and efficacy of INC280 in patients with solid tumors that are refractory to current treatment or for which there is not a current standard of care and whose tumors have dysregulation of the c-MET pathway.

NCT ID: NCT01323946 Completed - Influenza Clinical Trials

Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children

Start date: April 18, 2011
Phase: Phase 2
Study type: Interventional

The objective of the study is to evaluate the immunogenicity and safety of prime-boost vaccination schedule of GSK Biologicals' investigational vaccine GSK1562902A.